Cartilage healing has been an intractable problem for millennia. Today, osteoarthritis, caused by cartilage damage, afflicts over 30 million people in the United States alone. Each patient will spend over $200,000 to treat this condition over his or her lifetime. Ultimately, current therapies fail to heal cartilage damage. Patients wait an average of 13 years to receive an end-stage treatment: an invasive and traumatic total joint replacement.
We are a company that creates cartilage regeneration products to eliminate the need for further treatments and improve patient quality of life. Using technologies developed at the University of California, Irvine, our team is creating a series of products to heal both focal and large defects in cartilage.
Hyaleon® is a 100% biological, mechanically robust cartilage implant capable of healing both large and small articular cartilage defects without the limitations of current treatments.
Melt-and-meld® is technology that repairs the early signs of cartilage injury and enhances cartilage integration.
Please note that Hyaleon® and Melt-and-meld® are not yet FDA-approved and therefore are currently limited by United States Law to animal and in vitro research use only. Hyaleon® and Melt-and-meld™ should not be used in humans.
SBIR Phase I: Evaluation of Hyaleon® pre-clinical safety and efficacy for healing large cartilage defects in the knee
SBIR Phase I: Development of a biological adhesive for the fixation and integration of cartilage implants